-
2023-508787-29-00
4
2024-10-10
Triple-negative early breast cancer with low risk for recurrence
-
2022-502751-61-00
4
2024-04-10
Advanced stage III, IVA, IVB laryngeal or II, III, IVA, IVB hypopharyn
-
2024-512782-14-00
7
2024-03-20
Treatment of Moderate to Severe Upper Facial Lines
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2023-504472-24-00
4
2024-03-19
Early Idiopathic Parkinson’s disease (PD)
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2023-503865-48-00
4
2024-02-16
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
-
2024-516634-35-00
6
2024-02-01
Convulsive or nonconvulsive benzodiazepine-resistant (established) sta
-
2022-503114-23-00
3
2023-12-19
Breast Cancer
-
2022-500453-16-00
4
2023-10-30
Multiple Myeloma
-
2024-517966-40-00
4
2023-07-13
Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
-
2022-500783-35-00
5
2022-12-06
Acute Myeloid Leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-512222-28-00
10
2015-06-02
Newly diagnosed with an intracranial or spinal ependymoma (all WHO gra
-
2024-515524-36-00
5
2025-05-30
Chronic Weight Management
-
2022-501457-37-00
5
2024-10-28
Myeloid Leukemia in Children with Down Syndrome
-
2023-506906-38-00
5
2024-05-23
Follicular Lymphoma